21. The polypeptide of any one of claims 9, 10, 13 or 14 wherein the first proximal end is within short repeat 3 of repeat portion VIII of toxin A (amino acids 2687-2710) and the second proximal end is within short repeat 4 of repeat portion II of toxin B (amino acids 1988-2007).
22. The polypeptide of claim 16 wherein the first proximal end is within amino acids 2700-2710 of toxin A and the second proximal end is within amino acids 1960-1970 of toxin B.
23. The polypeptide of claims 16 wherein the first proximal end is within amino acids 2680-2690 of toxin A and the second proximal end is within amino acids 1960-1970 of toxin B.
24. The polypeptide of claims 16 wherein the first proximal end is within amino acids 2700-2710 of toxin A and the second proximal end is within amino acids 1988-1998 of toxin B.
25. The polypeptide of claim 16 wherein the first proximal end is within amino acids 2680-2690 and the second proximal end is within amino acids 1860-1878.
~~26. The polypeptide of any preceding claim wherein the polypeptide is part of a larger fusion protein.~~
~~27.~~26. The polypeptide of any preceding claim wherein the polypeptide comprises an immunogenic fragment of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 or SEQ ID NO:27.
~~28.~~27. The polypeptide of any preceding claim wherein the polypeptide comprises an immunogenic fragment of at least 500, 600, 700, 750, 800, 850 or 900 amino acids of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 or SEQ ID NO:27.
~~29.~~28. The polypeptide of any preceding claim wherein the polypeptide comprises more than 450, 475, 500, 525, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825 or 850 amino acids from toxin A.
~~30.~~29. The polypeptide of any preceding claim wherein the polypeptide comprises less than 850, 825, 800, 775, 750, 725, 700, 675, 650, 625, or 600 amino acids from toxin A.
~~31.~~30. The polypeptide of any preceding claim wherein the polypeptide comprises more than 350, 375, 400, 425, 450, 475, 500 or 525 amino acids from toxin B.
~~32.~~31. The polypeptide of any preceding claim wherein the polypeptide comprises less than 525, 500, 475, or 450 amino acids from toxin B.
~~33.~~32. A polynucleotide encoding the polypeptide of any one of claims 1-~~32~~31.
~~34.~~33. A vector comprising the polynucleotide of claim ~~33~~ 32 linked to an inducible promoter.
~~35.~~34. An immunogenic composition comprising the polypeptide of any one of claims 1-~~32~~ 31 and a pharmaceutically acceptable excipient.
~~36.~~35. The immunogenic composition of claim ~~35~~ 34 further comprising an adjuvant.
~~37. The immunogenic composition of any one of claims 35-36 further comprising additional antigens.~~
~~38. The immunogenic composition of claim 37 wherein the additional antigens are antigens derived from a bacterium selected from the group consisting of *S.pneumoniae*, *H.influenzae*, *N.meningitidis*, *E.coli*, *M.cattarhalis*, tetanus, diphtheria, pertussis, *S.epidermidis*, enterococci, and *S.aureus*.~~
~~39.~~36. A vaccine comprising the immunogenic composition of any one of claims ~~35~~34-~~38~~35.
~~40.~~37. The immunogenic composition of any one of claims ~~35~~34-~~38~~ 35 or the vaccine of claim ~~39~~ 36 for use in the treatment or prevention of *C.difficile* disease.
~~41.~~38. A use of the immunogenic composition of any one of claims ~~35~~34-~~38~~ 35 or the vaccine of claim ~~39~~ 36 in the preparation of a medicament for the prevention or treatment of *C.difficile* disease.